Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder

Lack of treatment response is a critical problem in major depressive disorder (MDD). Cariprazine is a D(3)-preferring dopamine D(3)/D(2) receptor partial agonist and 5-HT(1A) partial agonist. This phase 3, multicenter, open-label, long-term (26-week), flexible-dose (1.5–4.5 mg/day) study assessed th...

Descripción completa

Detalles Bibliográficos
Autores principales: Vieta, Eduard, Earley, Willie R., Burgess, Maria V., Durgam, Suresh, Chen, Changzheng, Zhong, Yan, Barabássy, Ágota, Németh, György
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams And Wilkins 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369898/
https://www.ncbi.nlm.nih.gov/pubmed/30531358
http://dx.doi.org/10.1097/YIC.0000000000000246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369898/
https://www.ncbi.nlm.nih.gov/pubmed/30531358
http://dx.doi.org/10.1097/YIC.0000000000000246

Ejemplares similares